Research programme: antibody-based cancer therapeutics - MabSpace Biosciences

Drug Profile

Research programme: antibody-based cancer therapeutics - MabSpace Biosciences

Alternative Names: MSB 2311

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabSpace Biosciences
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Mar 2017 Research programme: antibody-based cancer therapeutics - MabSpace Biosciences is available for licensing in (excluding China) as of 23 Feb 2017.
  • 23 Feb 2017 MabSpace intends to file an IND application with the CFDA in China for Cancers
  • 23 Feb 2017 MabSpace plans a first in-human trial for Cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top